 Olivia Irby
Concepts (123)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Systemic Inflammatory Response Syndrome | 10 | 2023 | 55 | 1.170 |
Why?
| | Hospitalization | 17 | 2024 | 665 | 0.960 |
Why?
| | Child | 35 | 2024 | 6862 | 0.840 |
Why?
| | Status Asthmaticus | 1 | 2022 | 6 | 0.790 |
Why?
| | Hypokalemia | 1 | 2022 | 10 | 0.790 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 290 | 0.640 |
Why?
| | Adolescent | 20 | 2024 | 6459 | 0.490 |
Why?
| | Factor Xa | 1 | 2014 | 7 | 0.470 |
Why?
| | Child, Hospitalized | 3 | 2022 | 30 | 0.440 |
Why?
| | Heparin | 1 | 2014 | 91 | 0.440 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2023 | 55 | 0.390 |
Why?
| | Influenza, Human | 2 | 2022 | 83 | 0.380 |
Why?
| | Anticoagulants | 1 | 2014 | 253 | 0.380 |
Why?
| | Thrombosis | 1 | 2014 | 249 | 0.370 |
Why?
| | Infant | 12 | 2024 | 3584 | 0.360 |
Why?
| | Nervous System Diseases | 2 | 2023 | 88 | 0.360 |
Why?
| | Humans | 38 | 2024 | 50201 | 0.360 |
Why?
| | Child, Preschool | 12 | 2024 | 3896 | 0.360 |
Why?
| | Vaccines, Synthetic | 4 | 2022 | 22 | 0.350 |
Why?
| | Intensive Care Units, Pediatric | 4 | 2024 | 171 | 0.330 |
Why?
| | United States | 13 | 2024 | 4898 | 0.310 |
Why?
| | Case-Control Studies | 7 | 2023 | 1145 | 0.280 |
Why?
| | Critical Illness | 4 | 2022 | 301 | 0.270 |
Why?
| | Vaccination | 6 | 2023 | 275 | 0.270 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2022 | 76 | 0.230 |
Why?
| | Intensive Care Units | 5 | 2023 | 224 | 0.230 |
Why?
| | Immunocompromised Host | 1 | 2024 | 119 | 0.220 |
Why?
| | Meningitis, Aseptic | 1 | 2023 | 2 | 0.220 |
Why?
| | Female | 17 | 2024 | 26829 | 0.220 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 34 | 0.220 |
Why?
| | Connective Tissue Diseases | 1 | 2023 | 16 | 0.210 |
Why?
| | Guillain-Barre Syndrome | 1 | 2023 | 10 | 0.210 |
Why?
| | Retrospective Studies | 6 | 2023 | 6190 | 0.210 |
Why?
| | Interferon Type I | 1 | 2022 | 24 | 0.210 |
Why?
| | Respiratory Tract Infections | 1 | 2023 | 76 | 0.210 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 19 | 0.200 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2022 | 3 | 0.200 |
Why?
| | Tachycardia, Supraventricular | 1 | 2022 | 39 | 0.200 |
Why?
| | Influenza Vaccines | 1 | 2022 | 31 | 0.200 |
Why?
| | Coinfection | 1 | 2022 | 42 | 0.200 |
Why?
| | Male | 14 | 2024 | 25572 | 0.190 |
Why?
| | Albuterol | 1 | 2022 | 56 | 0.190 |
Why?
| | Young Adult | 6 | 2024 | 4052 | 0.180 |
Why?
| | Bronchodilator Agents | 1 | 2022 | 75 | 0.180 |
Why?
| | Infant, Newborn | 5 | 2024 | 2770 | 0.180 |
Why?
| | Multiple Organ Failure | 1 | 2020 | 47 | 0.180 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2021 | 100 | 0.170 |
Why?
| | Patient Discharge | 4 | 2022 | 322 | 0.170 |
Why?
| | Glucocorticoids | 1 | 2021 | 230 | 0.160 |
Why?
| | Asthma | 1 | 2022 | 282 | 0.160 |
Why?
| | Aftercare | 3 | 2022 | 74 | 0.150 |
Why?
| | Patient Acuity | 3 | 2022 | 15 | 0.150 |
Why?
| | Stroke | 1 | 2023 | 479 | 0.150 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 562 | 0.140 |
Why?
| | Prospective Studies | 4 | 2024 | 2396 | 0.140 |
Why?
| | Pregnancy | 4 | 2023 | 2609 | 0.120 |
Why?
| | Erythrocyte Transfusion | 1 | 2014 | 50 | 0.120 |
Why?
| | Whole Blood Coagulation Time | 1 | 2014 | 6 | 0.120 |
Why?
| | Cohort Studies | 3 | 2024 | 1414 | 0.120 |
Why?
| | Seasons | 2 | 2023 | 81 | 0.100 |
Why?
| | Adult | 6 | 2024 | 13486 | 0.100 |
Why?
| | Oxygen | 1 | 2014 | 321 | 0.100 |
Why?
| | Hospital Mortality | 2 | 2024 | 409 | 0.090 |
Why?
| | Mothers | 2 | 2023 | 256 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2024 | 1097 | 0.090 |
Why?
| | Disease Progression | 2 | 2023 | 821 | 0.080 |
Why?
| | Logistic Models | 2 | 2022 | 901 | 0.080 |
Why?
| | Age Factors | 2 | 2022 | 1096 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 1580 | 0.070 |
Why?
| | Pandemics | 2 | 2023 | 567 | 0.070 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 235 | 0.070 |
Why?
| | Risk Factors | 2 | 2023 | 3644 | 0.060 |
Why?
| | RNA, Messenger, Stored | 1 | 2023 | 4 | 0.060 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2023 | 12 | 0.060 |
Why?
| | Crowding | 1 | 2023 | 14 | 0.050 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2023 | 2 | 0.050 |
Why?
| | Receptor, Notch1 | 1 | 2023 | 4 | 0.050 |
Why?
| | NF-kappa B p52 Subunit | 1 | 2022 | 6 | 0.050 |
Why?
| | Family Characteristics | 1 | 2023 | 50 | 0.050 |
Why?
| | Haploinsufficiency | 1 | 2022 | 14 | 0.050 |
Why?
| | Administration, Intravenous | 1 | 2023 | 70 | 0.050 |
Why?
| | Immunoassay | 1 | 2022 | 20 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2022 | 2 | 0.050 |
Why?
| | Influenza B virus | 1 | 2022 | 6 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 82 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2022 | 43 | 0.050 |
Why?
| | Neutralization Tests | 1 | 2022 | 24 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 113 | 0.050 |
Why?
| | Viral Envelope Proteins | 1 | 2022 | 33 | 0.050 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2022 | 15 | 0.050 |
Why?
| | Autoantibodies | 1 | 2022 | 114 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2022 | 28 | 0.050 |
Why?
| | Life Support Care | 1 | 2022 | 17 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2022 | 91 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2022 | 94 | 0.050 |
Why?
| | Research Design | 1 | 2024 | 344 | 0.050 |
Why?
| | Immunization, Secondary | 1 | 2022 | 21 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2021 | 13 | 0.050 |
Why?
| | Inpatients | 1 | 2023 | 193 | 0.050 |
Why?
| | Immunomodulation | 1 | 2021 | 37 | 0.050 |
Why?
| | NF-kappa B | 1 | 2022 | 315 | 0.050 |
Why?
| | Shock | 1 | 2021 | 34 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2022 | 682 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 244 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2023 | 208 | 0.050 |
Why?
| | Propensity Score | 1 | 2021 | 126 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2021 | 5203 | 0.040 |
Why?
| | Stroke Volume | 1 | 2021 | 132 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 395 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 382 | 0.040 |
Why?
| | Comorbidity | 1 | 2022 | 612 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 639 | 0.040 |
Why?
| | Critical Care | 1 | 2021 | 215 | 0.040 |
Why?
| | Registries | 1 | 2022 | 527 | 0.040 |
Why?
| | Body Mass Index | 1 | 2022 | 658 | 0.040 |
Why?
| | Inflammation | 1 | 2023 | 608 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1041 | 0.040 |
Why?
| | Length of Stay | 1 | 2020 | 627 | 0.030 |
Why?
| | Time Factors | 1 | 2022 | 2909 | 0.030 |
Why?
| | Hematocrit | 1 | 2014 | 45 | 0.030 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2014 | 53 | 0.030 |
Why?
| | Obesity | 1 | 2022 | 1112 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2014 | 128 | 0.030 |
Why?
|
|
Irby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|